Diabetes Mellitus, Non-Insulin-Dependent

Metabolic Diseases
12
Pipeline Programs
7
Companies
19
Clinical Trials
5
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
4
7
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Peptide
150%
+ 7 programs with unclassified modality

On Market (5)

Approved therapies currently available

Sanofi
AMARYLApproved
glimepiride
Sanofi
oral1995
Sanofi
LANTUSApproved
insulin glargine
Sanofi
Insulin Analog [EPC]injection2000
Sanofi
LANTUS SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]injection2000
Sanofi
TOUJEO MAX SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]subcutaneous2015
Sanofi
TOUJEO SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]subcutaneous2015

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
2 programs
2
1
GlimepiridePhase 35 trials
insulin glarginePhase 31 trial
Active Trials
NCT02395237Withdrawn0Est. Dec 2015
NCT01699932Completed167Est. Apr 2014
NCT01459809Completed538Est. Jan 2014
+3 more trials
Bristol Myers Squibb
2 programs
1
1
GlucovancePhase 41 trial
GlucovancePhase 31 trial
Active Trials
NCT00035542CompletedEst. Oct 2003
NCT00035568CompletedEst. Jun 2003
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
Liraglutide or PlaceboPhase 4Peptide1 trial
Active Trials
NCT02299388Completed11Est. Dec 2016
Novartis
NovartisBASEL, Switzerland
1 program
1
LAF237 = vildagliptinPhase 3Small Molecule1 trial
Active Trials
NCT00952991Completed18Est. Feb 2006
TP
1 program
1
Metformin EicosapentaenoatePhase 11 trial
Active Trials
NCT02113163Completed32Est. Jul 2014
Pfizer
PfizerNEW YORK, NY
1 program
Glipizide GITSN/A1 trial
Active Trials
NCT00550329Completed32Est. Nov 2007
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEAN/A1 trial
Active Trials
NCT01694758Completed733Est. Mar 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskLiraglutide or Placebo
SanofiGlimepiride
SanofiGlimepiride
SanofiGlimepiride
SanofiGlimepiride
SanofiGlimepiride
Bristol Myers SquibbGlucovance
SanofiGlimepiride
SanofiGlimepiride
SanofiGlimepiride
SanofiGlimepiride
NovartisLAF237 = vildagliptin
Sanofiinsulin glargine
Bristol Myers SquibbGlucovance
SanofiGlimepiride

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 15,717 patients across 19 trials

NCT02299388Novo NordiskLiraglutide or Placebo

To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study

Start: Oct 2014Est. completion: Dec 201611 patients
Phase 4Completed
NCT01204580SanofiGlimepiride

ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination

Start: Dec 2010Est. completion: Mar 201240 patients
Phase 4Completed
NCT01144728SanofiGlimepiride

Initiation and Titration of Amaryl

Start: May 2010Est. completion: Dec 2010172 patients
Phase 4Completed
NCT00957060SanofiGlimepiride

Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients

Start: Jul 2009Est. completion: Oct 2010400 patients
Phase 4Completed
NCT00908921SanofiGlimepiride

Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)

Start: Apr 2009Est. completion: Sep 2010391 patients
Phase 4Completed
NCT00633425SanofiGlimepiride

Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride

Start: Oct 2002Est. completion: Oct 200343 patients
Phase 4Completed
NCT00035568Bristol Myers SquibbGlucovance

A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes

Start: Feb 2002Est. completion: Jun 2003
Phase 4Completed
NCT01699932SanofiGlimepiride

Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled

Start: Sep 2012Est. completion: Apr 2014167 patients
Phase 3Completed
NCT01459809SanofiGlimepiride

Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients

Start: Feb 2012Est. completion: Jan 2014538 patients
Phase 3Completed
NCT01457911SanofiGlimepiride

Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin

Start: Oct 2011Est. completion: Feb 2013244 patients
Phase 3Completed
NCT00924573SanofiGlimepiride

Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride

Start: May 2009Est. completion: Mar 2010189 patients
Phase 3Completed
NCT00952991NovartisLAF237 = vildagliptin

The Effects of LAF237 on Gastric Function in Type 2 Diabetes

Start: May 2005Est. completion: Feb 200618 patients
Phase 3Completed
NCT00069784Sanofiinsulin glargine

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

Start: Aug 2003Est. completion: Dec 201112,537 patients
Phase 3Completed
NCT00035542Bristol Myers SquibbGlucovance

A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.

Start: Dec 2001Est. completion: Oct 2003
Phase 3Completed
NCT00044447SanofiGlimepiride

Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

Start: May 2001Est. completion: Sep 2002170 patients
Phase 3Completed
NCT02395237SanofiGlimepiride

COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.

Start: May 2015Est. completion: Dec 20150
Phase 1Withdrawn
NCT02113163Thetis PharmaceuticalsMetformin Eicosapentaenoate

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

Start: Mar 2014Est. completion: Jul 201432 patients
Phase 1Completed
NCT01694758AstraZenecaOPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA

OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA

Start: Nov 2012Est. completion: Mar 2014733 patients
N/ACompleted
NCT00550329PfizerGlipizide GITS

Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets

Start: Oct 2007Est. completion: Nov 200732 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
20h ago

(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)

Johnson & Johnson
Beerse, Antwerp, Belgium
Yesterday

Computational Chemist

Topos Bio
San Francisco Office
2d ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr

Senior Specialist, Quality Management Systems

Crinetics Pharmaceuticals
San Diego, CA
4d ago
$91K - $114K/yr

Director, Quality Systems, Project Management, QRM, RS

Crinetics Pharmaceuticals
US California
4d ago
$178K - $223K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)